<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">INTERFERON ALFA-n1 LYMPHOBLASTOID</span><br/>(in-ter-fer'on)<br/><span class="topboxtradename">Wellferon<br/></span><b>Classifications:</b> <span class="classification"> immunomodulator</span>; <span class="classification">antiviral</span><br/><b>Prototype: </b>Interferon alfa-2a<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>3 MU/mL vial</p>
<h1><a name="action">Actions</a></h1>
<p>Interferon alfa-n1 is a blend of human alpha interferons following induction of a virus into leukocytes. <b>Antiviral Action:</b> Wellferon reprograms virus-infected cells to inhibit various stages of viral replication.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effectiveness indicated by reduction in serum ALT and HCV viral load. <b>Antitumor Action:</b> Suppresses cell proliferation. <b>Immunomodulating Action:</b> Enhances phagocytic activity of macrophages and augments cytotoxicity of lymphocyte natural killer (NK) cells.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of chronic hepatitis C.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to alpha interferons; history of anaphylaxis to bovine immunoglobulins, egg protein, polymycin B, or neomycin
         B; pregnancy (category C); lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hepatitis from causes other than hepatitis C; psychiatric disorder; hypertension, supraventricular arrhythmias, MI, hypotension;
         seizures; hypothyroidism; hepatic dysfunction; older adults; autoimmune disease; leukopenia; pulmonary dysfunction; concurrent
         use of immunosuppressive agents. Safety and efficacy in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Chronic Hepatitis C</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC/IM</span> 3 MU 3 times/wk times 48 wk<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Subcutaneous/</span><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Administer undiluted IM or SC as ordered. Do not shake vial.</li>
<li>Do not initiate therapy unless acceptable baseline lab values have been attained. Platelet count <img src="../images/special/greaterorequal.gif"/>75
            <small>x</small> 10<sup>9</sup>/L, Hgb <img src="../images/special/greaterorequal.gif"/>100 g/L, ANC <img src="../images/special/greaterorequal.gif"/>1500
            <small>x</small> 10<sup>6</sup>/L, serum creatinine 25 g/L, bilirubin WNL, TSH,
            and T<sub>4</sub> WNL.
         </li>
<li>Refrigerate between 2°8° C (36°46° F) and protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span>
<span class="speceff-common">Asthenia, headache, fever, chills, injection site reaction (pain, edema, hemorrhage, inflammation), pain, myalgia, arthralgia</span>. <span class="typehead">CNS:</span>
<span class="speceff-common">Anxiety, nervousness, insomnia, somnolence, depression,</span> dizziness, confusion, abnormal thinking, amnesia, paresthesia. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, diarrhea, abdominal pain,</span> anorexia, vomiting, weight loss, hepatotoxicity, <span class="typehead">Hematologic:</span> Thrombocytopenia, leukopenia, anemia. <span class="typehead">Respiratory:</span> Cough, bronchitis, dyspnea, pneumonia, rhinitis, pharyngitis. <span class="typehead">Skin:</span>
<span class="speceff-common">Alopecia,</span> rash, dry skin, pruritus, urticaria, sweat. 
      <h1><a name="interactions">Interactions</a></h1>No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 40100% absorbed from SC or IM site. <span class="typehead">Peak:</span> 69 h. <span class="typehead">Metabolism:</span> Renal and cellular catabolism. <span class="typehead">Half-Life:</span> 710 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for S&amp;S of depression, suicidal ideation, other CNS effects.</li>
<li>Monitor cardiovascular status carefully especially with preexisting CV disease. Do baseline and periodic EKG throughout therapy.</li>
<li>Lab tests: Monitor baseline and q3mo TSH and T<sub>4</sub>; monitor baseline and periodic Hgb and Hct, CBC with differential, platelet count, liver functions.
         </li>
<li>Assess hydration status; good hydration especially important during initial stage of treatment.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn appropriate self-injection techniques. Do not reuse syringes.</li>
<li>Relieve flu-like symptoms with acetaminophen or anti-inflammatory analgesic.</li>
<li>Drink plenty of fluids especially in the initial weeks of treatment.</li>
<li>Do not accept interferon brand changes without first consulting physician.</li>
<li>Use reliable contraception.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>